Ryanodex (dantrolene sodium) for injectable suspension
Phase 2Terminated 1 views this week 0 watching💤 Quiet
Interest: 17/100
17
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Drug Toxicity Psychotropic Agents Psychostimulants
Conditions
Drug Toxicity Psychotropic Agents Psychostimulants
Trial Timeline
Aug 12, 2017 → Dec 31, 2018
NCT ID
NCT03189433About Ryanodex (dantrolene sodium) for injectable suspension
Ryanodex (dantrolene sodium) for injectable suspension is a phase 2 stage product being developed by Eagle Pharmaceuticals for Drug Toxicity Psychotropic Agents Psychostimulants. The current trial status is terminated. This product is registered under clinical trial identifier NCT03189433. Target conditions include Drug Toxicity Psychotropic Agents Psychostimulants.
What happened to similar drugs?
8 of 15 similar drugs in Drug Toxicity Psychotropic Agents Psychostimulants were approved
Approved (8) Terminated (3) Active (5)
✅Polyene phosphatidylcholine injection 930 mg QD + Magnesium Isoglycyrrhizinate injection 200 mg QDHaisco Pharmaceutical GroupApproved
Hype Score Breakdown
Clinical
12
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03189433 | Phase 2 | Terminated |
Competing Products
20 competing products in Drug Toxicity Psychotropic Agents Psychostimulants